

TABLES – SUPPLEMENTARY MATERIAL

TABLE S1. Demographic, clinical and serological features according to the presence of ILD in the replication sample

	Replication sample <i>n</i> :75	RA-ILD <i>n</i> :25	Non-ILD RA <i>n</i> :50	<i>p</i> value
Female (%)	40 (53)	14 (56)	26 (52)	NS
Mean age (\pm SD)	66.7 \pm 8.8	68.6 \pm 10.5	65.7 \pm 7.6	NS
Mean disease duration (\pm SD)	8.7 \pm 11.1	8.4 \pm 9.5	8.9 \pm 11.9	NS
Smoking cumulative dose (\pm SD)	19.8 \pm 20.1	14.3 \pm 20.0	22.6 \pm 19.7	NS
Erosive disease (%)	40 (53)	15 (60)	25 (50)	NS
ACPA (%)	65 (87)	24 (96)	41 (82)	NS
Median titer ACPA (IQR) CU	250 (324)	250 (308)	250 (367)	NS
RF (%)	52 (69)	23 (92)	29 (58)	<0.005
Median titer RF (IQR) IU	83 (284)	165 (559)	38 (194)	<0.005
Anti-FCS (%)	47 (63)	23 (92)	24 (48)	<0.005
Median titer Anti-FCS (IQR) AU/mL	545 (1875)	1571 (1316)	171 (977)	<0.005
Anti-Fib (%)	48 (64)	19 (76)	29 (58)	NS
Median titer Anti-Fib (IQR) AU/mL	282 (335)	407 (418)	225 (277)	0.028
Anti-CFFHP (%)	18 (24)	9 (36)	9 (18)	NS
Median titer Anti-CFFHP (IQR) AU/mL	0 (118)	0 (598)	0 (54)	NS

ACPA: anti-citrullinated protein antibodies; RF: rheumatoid factor; Anti-FCS: IgG antibodies against carbamylated fetal calf serum; Anti-Fib: IgG antibodies against carbamylated fibrinogen; Anti-CFFHP: IgG antibodies against carbamylated fibrine/filagrine homocitrullinated peptide; IQR: interquartile range; CU: chemiluminescence units; IU: international units; AU: arbitrary unit; \pm SD: standard deviation; NS: Not significant.

TABLE S2. Anti-CarP positivity according to the smoking status in the main population

		Anti-FCS		Anti-Fib		Anti-CFFHP		Anti-FCS-IgA	
		positive <i>n</i> (%)	<i>p</i> value	positive <i>n</i> (%)	<i>p</i> value	positive <i>n</i> (%)	<i>p</i> value	positive <i>n</i> (%)	<i>p</i> value
Smoking status	Ever <i>n</i> : 83	48 (58)	0.022	54 (65)	0.021	22 (27)	NS	31 (37)	0.003
	Non-ever <i>n</i> : 96	39 (41)		46 (48)		19 (20)		17 (18)	
	Current <i>n</i> : 30	20 (67)	0.030	23 (77)	0.012	5 (17)	NS	15 (50)	0.002
	Non-current <i>n</i> : 149	67 (45)		77 (52)		36 (24)		33 (22)	

Anti-FCS: IgG antibodies against carbamylated fetal calf serum; Anti-Fib: IgG antibodies against carbamylated fibrinogen; Anti-CFFHP: IgG antibodies against carbamylated fibrine/filagrine homocitrullinated peptide; Anti-FCS-IgA: IgA antibodies against carbamylated fetal calf serum; NS: not significant.

TABLE S3. Smoking cumulative dose according to Anti-CarP positivity in the main population

	Anti-FCS			Anti-Fib			Anti-CFFHP			Anti-FCS-IgA		
	positive n: 48	negative n: 35	p value	positive n: 54	negative n: 29	p value	positive n: 22	negative n: 61	p value	positive n: 31	negative n: 52	p value
Mean smoking cumulative dose (\pm SD)	25.1 \pm 12.9	22.6 \pm 13.4	NS	24.2 \pm 12.9	23.8 \pm 13.4	NS	25.3 \pm 10.8	23.6 \pm 13.8	NS	26.0 \pm 12.7	22.9 \pm 13.2	NS

Anti-FCS: IgG antibodies against carbamylated fetal calf serum; Anti-Fib: IgG antibodies against carbamylated fibrinogen; Anti-CFFHP: IgG antibodies against carbamylated fibrine/filagrine homocitrullinated peptide; Anti-FCS-IgA: IgA antibodies against carbamylated fetal calf serum; \pm SD: standard deviation; NS: not significant